Targeting the cis-dimerization of LINGO-1 with low MW compounds affects its downstream signalling

British Journal of Pharmacology

Volumn 172, Issue 3, 2015, Pages 841-856

  Cobret, L ^a   De Tauzia, M L ^a   Ferent, J ^b   Traiffort, E ^c   Henaoui I ^d   Godin, F ^a   Kellenberger, E ^e,f   Rognan, D ^e,f   Pantel, J ^g   Benedetti H ^a   Morisset Lopez, Séverine ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c Universite Paris Sud   (France)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f Medalis Drug Discovery Center   (France)

^g CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; HOMODIMER; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHENOXYBENZAMINE; PROTEIN LINGO 1; SEROTONIN RECEPTOR; SMALL MOLECULE PROTEIN PROTEIN INTERACTION MODULATOR; UNCLASSIFIED DRUG; LINGO1 PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BRAIN CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL SURVIVAL; CIS ISOMER; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; ENZYME PHOSPHORYLATION; FEMALE; HEK293 CELL LINE; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR WEIGHT; NONHUMAN; OLIGOMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; RAT; VALIDATION STUDY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

CELL LINE, TUMOR; DIMERIZATION; HEK293 CELLS; HUMANS; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NERVE TISSUE PROTEINS; PHENOXYBENZAMINE; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920815188     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12945     Document Type: Article

References (67)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Arkin MR, Wells JA (2004). Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301-317.
5. Bacart J, Corbel C, Jockers R, Bach S, Couturier C (2008). The BRET technology and its application to screening assays. Biotechnol J 3: 311-324.
6. Barrette B, Vallieres N, Dube M, Lacroix S (2007). Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. Mol Cell Neurosci 34: 519-538.
7. Bessero AC, Clarke PG (2010). Neuroprotection for optic nerve disorders. Curr Opin Neurol 23: 10-15.
8. Bibel M, Hoppe E, Barde YA (1999). Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J 18: 616-622.
9. Bouvier M, Heveker N, Jockers R, Marullo S, Milligan G (2007). BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods 4: 3-4.
10. Bulenger S, Marullo S, Bouvier M (2005). Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 26: 131-137.
11. Carim-Todd L, Escarceller M, Estivill X, Sumoy L (2003). LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. Eur J Neurosci 18: 3167-3182.
12. Cooper J, Hill SJ, Alexander SP (1997). An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells. Br J Pharmacol 122: 546-550.
13. Couturier C, Deprez B (2012). Setting up a bioluminescence resonance energy transfer high throughput screening assay to search for protein/protein interaction inhibitors in mammalian cells. Front Endocrinol (Lausanne) 3: 1-13.
14. Couturier C, Jockers R (2003). Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers. J Biol Chem 278: 26604-26611.
15. De Vries L, Finana F, Cachoux F, Vacher B, Sokoloff P, Cussac D (2010). Cellular BRET assay suggests a conformational rearrangement of preformed TrkB/Shc complexes following BDNF-dependent activation. Cell Signal 22: 158-165.
16. Ferre S, Casado V, Devi LA, Filizola M, Jockers R, Lohse MJ et al. (2014). G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 66: 413-434.
17. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A (2001). Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem 276: 31279-31284.
18. Fry DC (2008). Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Protein Pept Sci 9: 240-247.
19. Gerin CG, Madueke IC, Perkins T, Hill S, Smith K, Haley B et al. (2011). Combination strategies for repair, plasticity, and regeneration using regulation of gene expression during the chronic phase after spinal cord injury. Synapse 65: 1255-1281.
20. Grimm I, Messemer N, Stanke M, Gachet C, Zimmermann H (2009). Coordinate pathways for nucleotide and EGF signaling in cultured adult neural progenitor cells. J Cell Sci 122 (Pt 14): 2524-2533.
21. Huang CL, Kuo E, Toto RD (2008). WNK kinases and essential hypertension. Curr Opin Nephrol Hypertens 17: 133-137.
22. Inoue H, Lin L, Lee X, Shao Z, Mendes S, Snodgrass-Belt P et al. (2007). Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A 104: 14430-14435.
23. Issad T, Blanquart C, Gonzalez-Yanes C (2007). The use of bioluminescence resonance energy transfer for the study of therapeutic targets: application to tyrosine kinase receptors. Expert Opin Ther Targets 11: 541-556.
24. James JR, Oliveira MI, Carmo AM, Iaboni A, Davis SJ (2006). A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. Nat Methods 3: 1001-1006.
25. Jepson S, Vought B, Gross CH, Gan L, Austen D, Frantz JD et al. (2012). LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem 287: 22184-22195.
26. Ji B, Li M, Wu WT, Yick LW, Lee X, Shao Z et al. (2006a). LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci 33: 311-320.
27. Ji SP, Zhang Y, Van Cleemput J, Jiang W, Liao M, Li L et al. (2006b). Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med 12: 324-329.
28. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
30. Kwon HS, Nakaya N, Abu-Asab M, Kim HS, Tomarev SI (2014). Myocilin is involved in NgR1/Lingo-1-mediated oligodendrocyte differentiation and myelination of the optic nerve. J Neurosci 34: 5539-5551.
31. Lee X, Yang Z, Shao Z, Rosenberg SS, Levesque M, Pepinsky RB et al. (2007). NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci 27: 220-225.
32. Liu XJ, Gingrich JR, Vargas-Caballero M, Dong YN, Sengar A, Beggs S et al. (2008). Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nat Med 14: 1325-1332.
33. Llorens F, Gil V, Iraola S, Carim-Todd L, Marti E, Estivill X et al. (2008). Developmental analysis of Lingo-1/Lern1 protein expression in the mouse brain: interaction of its intracellular domain with Myt1l. Dev Neurobiol 68: 521-541.
34. Loov C, Fernqvist M, Walmsley A, Marklund N, Erlandsson A (2012). Neutralization of LINGO-1 during in vitro differentiation of neural stem cells results in proliferation of immature neurons. PLoS ONE 7: e29771.
35. Ma D, Zerangue N, Lin YF, Collins A, Yu M, Jan YN et al. (2001). Role of ER export signals in controlling surface potassium channel numbers. Science 291: 316-319.
36. Mandai K, Guo T, St Hillaire C, Meabon JS, Kanning KC, Bothwell M et al. (2009). LIG family receptor tyrosine kinase-associated proteins modulate growth factor signals during neural development. Neuron 63: 614-627.
37. Maruyama IN (2014). Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Cells 3: 304-330.
38. McDonald CL, Bandtlow C, Reindl M (2011). Targeting the Nogo receptor complex in diseases of the central nervous system. Curr Med Chem 18: 234-244.
39. McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
40. Mi S (2008). Troy/Taj and its role in CNS axon regeneration. Cytokine Growth Factor Rev 19: 245-251.
41. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J et al. (2004). LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 7: 221-228.
42. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z et al. (2005). LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 8: 745-751.
43. Mi S, Sandrock A, Miller RH (2008). LINGO-1 and its role in CNS repair. Int J Biochem Cell Biol 40: 1971-1978.
44. Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W et al. (2009). Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 65: 304-315.
45. Mosyak L, Wood A, Dwyer B, Buddha M, Johnson M, Aulabaugh A et al. (2006). The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. J Biol Chem 281: 36378-36390.
46. Okafuji T, Tanaka H (2005). Expression pattern of LINGO-1 in the developing nervous system of the chick embryo. Gene Expr Patterns 6: 57-62.
47. Park JB, Yiu G, Kaneko S, Wang J, Chang J, He XL et al. (2005). A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 45: 345-351.
48. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
49. Pichon X, Wattiez AS, Becamel C, Ehrlich I, Bockaert J, Eschalier A et al. (2010). Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain. Mol Ther 18: 1462-1470.
50. Qi Q, He K, Liu X, Pham C, Meyerkord C, Fu H et al. (2013). Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation. Oncogene 32: 1030-1040.
51. Ramsay D, Kellett E, McVey M, Rees S, Milligan G (2002). Homoand hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 365 (Pt 2): 429-440.
52. Rudick RA, Mi S, Sandrock AW Jr (2008). LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 8: 1561-1570.
53. Schlessinger J (2002). Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669-672.
54. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N et al. (2005). TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45: 353-359.
55. Siddiqui S, Cong WN, Daimon CM, Martin B, Maudsley S (2013). BRET biosensor analysis of receptor tyrosine kinase functionality. Front Endocrinol (Lausanne) 4: 46.
56. Simi A, Ibanez CF (2010). Assembly and activation of neurotrophic factor receptor complexes. Dev Neurobiol 70: 323-331.
57. Stein T, Walmsley AR (2012). The leucine-rich repeats of LINGO-1 are not required for self-interaction or interaction with the amyloid precursor protein. Neurosci Lett 509: 9-12.
58. Theroux TL, Esbenshade TA, Peavy RD, Minneman KP (1996). Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors. Mol Pharmacol 50: 1376-1387.
59. Thompson AD, Dugan A, Gestwicki JE, Mapp AK (2012). Fine-Tuning multiprotein complexes using small molecules. ACS Chem Biol 7: 1311-1320.
60. Wang L, Zhao H, Cui K, Yao L, Ren M, Hao A et al. (2012). Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening. Biosci Trends 6: 192-200.
61. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH et al. (1998). Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396: 679-682.
62. Xu BE, Stippec S, Lenertz L, Lee BH, Zhang W, Lee YK et al. (2004). WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J Biol Chem 279: 7826-7831.
63. Xu Y, Piston DW, Johnson CH (1999). A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc Natl Acad Sci U S A 96: 151-156.
64. Yamashita T, Fujitani M, Yamagishi S, Hata K, Mimura F (2005). Multiple signals regulate axon regeneration through the Nogo receptor complex. Mol Neurobiol 32: 105-111.
65. Zhang Z, Xu X, Zhang Y, Zhou J, Yu Z, He C (2009). LINGO-1 interacts with WNK1 to regulate nogo-induced inhibition of neurite extension. J Biol Chem 284: 15717-15728.
66. Zhao XH, Jin WL, Ju G (2007). An in vitro study on the involvement of LINGO-1 and Rho GTPases in Nogo-A regulated differentiation of oligodendrocyte precursor cells. Mol Cell Neurosci 36: 260-269.
67. Zhong X, Pocas J, Liu Y, Wu PW, Mosyak L, Somers W et al. (2009). Swift residue-screening identifies key N-glycosylated asparagines sufficient for surface expression of neuroglycoprotein Lingo-1. FEBS Lett 583: 1034-1038.